Inhibition of SETDB1 then limited AKT hyperactivation and reversed cetuximab resistance, even in Kirsten rat sarcoma virus (KRAS)-mutated CRC cells (Hou et al., 2020). This evidence concerns the gene KRAS and colorectal carcinoma.